Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404054 | 0.81 | CA2 (0.65) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL11646781 | 0.78 | MAPT (0.72) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL3068412 | 0.74 | MAPT (0.53) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL15512469 | 0.74 | SMN1; SMN2 (0.51) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL11642877 | 0.71 | ALDH1A1 (0.56) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL11643855 | 0.70 | ALDH1A1 (0.54) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL11649348 | 0.69 | MAPT (0.49) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL11647437 | 0.68 | ALDH1A1 (0.49) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL7660360 | 0.66 | MEN1 (0.49) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 | |
| SCHEMBL28923770 | 0.65 | L3MBTL1 (0.60) | MAPTSMN1; SMN2NPSR1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | MAPT 3380/4885SMN1; SMN2 3298/4885NPSR1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.